EMA Authorised: Darzalex (daratumumab)

View source ↗

Summary

Daratumumab (Darzalex) has been authorised by the EMA for its indicated use in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. Decision date: 11/06/2026. Accelerated assessment